This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignees: Harvard College, Memorial Sloan Kettering Cancer Center. Active years: 2026.
Company Filing History:
1 out of 3,071 
1 out of 618 
Years Active: 2026
Title: The Innovative Contributions of David K Miyamoto
Introduction
David K Miyamoto is a notable inventor based in Cambridge, MA. He has made significant contributions to the field of cancer research through his innovative work. His research focuses on targeted therapies that aim to improve treatment outcomes for patients suffering from certain types of cancers.
Latest Patents
David K Miyamoto holds a patent for "5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of IKZF2 degraders." This patent describes compounds that promote the targeted degradation of IKZF2, a protein associated with the pathology of cancers such as acute myeloid leukemia. The patent also includes pharmaceutical compositions comprising these compounds, as well as methods for treating cancer and promoting the degradation of IKZF2 in subjects or biological samples.
Career Highlights
Throughout his career, David has worked with prestigious institutions, including Harvard College and Memorial Sloan Kettering Cancer Center. His work in these organizations has allowed him to collaborate with leading experts in the field of cancer research.
Collaborations
Some of his notable coworkers include Christina M Woo and Michael Kharas. Their collaborative efforts have contributed to advancements in understanding and treating cancer.
Conclusion
David K Miyamoto's innovative work and patent contributions are paving the way for new cancer treatments. His dedication to research and collaboration with esteemed institutions highlight his commitment to improving patient outcomes.